Dylan Daniel
About Dylan Daniel
Dylan Daniel serves as the Vice President of Oncology and Immuno-Oncology Research at CytomX Therapeutics, a position he has held since 2018. He has extensive experience in the field, having previously worked at Novartis, UCSF, and Genentech, and holds a PhD in Microbiology and Immunology from the University of Colorado Anschutz Medical Campus.
Work at CytomX Therapeutics
Dylan Daniel has served as the Vice President of Oncology and Immuno-Oncology Research at CytomX Therapeutics since 2018. In this role, he focuses on advancing research initiatives in oncology and immuno-oncology, contributing to the development of innovative therapeutic solutions. His leadership is pivotal in guiding research strategies and fostering collaborations within the organization. CytomX Therapeutics, located in South San Francisco, CA, is known for its commitment to transforming cancer treatment through its proprietary Probody platform.
Previous Experience at Novartis Institutes for BioMedical Research
Prior to his current position, Dylan Daniel worked at Novartis Institutes for BioMedical Research as a Senior Scientist, also known as Research Investigator III, from 2008 to 2014. During his tenure, he contributed to various research projects aimed at understanding and developing treatments for complex diseases. His experience at Novartis provided him with a strong foundation in biomedical research and drug development.
Academic Background and Education
Dylan Daniel earned his Doctor of Philosophy (PhD) in Microbiology and Immunology from the University of Colorado Anschutz Medical Campus, where he studied from 1991 to 1996. He also holds a Bachelor of Science (BS) degree in Biochemistry, Biophysics, and Molecular Biology from the University of California, Davis, which he completed from 1987 to 1991. His educational background laid the groundwork for his extensive career in scientific research and development.
Research Experience at UCSF and Genentech
Dylan Daniel has significant research experience, having worked as a Postdoctoral Researcher at the University of California, San Francisco (UCSF) from 1996 to 2002. Following this, he was employed as a Scientist at Genentech from 2002 to 2008. In these roles, he engaged in various research projects that contributed to advancements in the field of oncology and immunology, enhancing his expertise and knowledge in these areas.